Yahoo Web Search

  1. Stan Crooke became the CEO of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in 1989. This analysis aims first to contrast CEO compensation with other companies that have similar market ...

  2. Here's What Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) P/E Is Telling Us

    Simply Wall St. via Yahoo FinanceOct 02 18:39 PM

    To keep it practical, we'll show how Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) P/E ratio could help you assess the value on offer. Eagle Pharmaceuticals has a price to ...

  3. Schleifer Leonard S. became the CEO of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in 1988. This report will, first, examine the CEO compensation levels in comparison to CEO ...

  4. Is Reata Pharmaceuticals, Inc.'s (NASDAQ:RETA) CEO Pay Fair?

    Simply Wall St. via Yahoo FinanceOct 01 11:22 AM

    Huff became the CEO of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) in 2002. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies ...

  5. So shareholders might well want to know whether insiders have been buying or selling shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Do Insider Transactions Matter? It ...

  6. A look at the shareholders of Cipher Pharmaceuticals Inc. (TSE:CPH) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while ...

  7. Every investor in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and ...

  8. If you're interested in Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN), then you might want to consider its beta (a measure of share price volatility) in order to understand how the ...

  9. Deciphera Pharmaceuticals, Inc. (DCPH) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of ...

  10. Allena Pharmaceuticals, Inc. (ALNA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one ...

  1. Ads
    related to Pharmaceuticals, Inc